Drug-drug interactions with direct oral anticoagulants in Belgian primary care patients with non-valvular atrial fibrillation
Victoria A. Fuchs, Lorène Zerah, Anne Spinewine, Séverine Henrard · 2026
Read Drug-drug interactions with direct oral anticoagulants in Belgian primary care patients with non-valvular atrial fibrillation by Victoria A. Fuchs, Lorène Zerah, Anne Spinewine, Séverine Henrard (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13402681.txt.
Description
Victoria A. Fuchs and colleagues measured drug interactions for direct oral anticoagulants in Belgian primary care for atrial fibrillation. Their 2026 retrospective study uses the THIN database for 2022 to 2023, covering patients with non-valvular atrial fibrillation, an irregular heartbeat that raises stroke risk. Blood thinners prevent clots, but interacting drugs can raise bleeding or clotting risk.
Among 5,637 patients and 13,334 prescriptions, 22.9 percent of patients had at least one interaction during the year, and 17.8 percent of prescriptions involved one, mostly pharmacodynamic, meaning additive effects rather than altered drug levels. Antidepressants, antiplatelets, and anti-inflammatory drugs led the list. Higher stroke-risk scores and multiple anticoagulant types raised interaction odds. The paper urges routine review of bleeding-risk combinations in primary care.
Catalog record
| CREATOR | Victoria A. Fuchs, Lorène Zerah, Anne Spinewine, Séverine Henrard |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 40 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |